Intervention Review

You have free access to this content

Progestin-only pills for contraception

  1. David A Grimes1,*,
  2. Laureen M Lopez2,
  3. Paul A O'Brien3,
  4. Elizabeth G. Raymond4

Editorial Group: Cochrane Fertility Regulation Group

Published Online: 13 NOV 2013

Assessed as up-to-date: 29 OCT 2013

DOI: 10.1002/14651858.CD007541.pub3


How to Cite

Grimes DA, Lopez LM, O'Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD007541. DOI: 10.1002/14651858.CD007541.pub3.

Author Information

  1. 1

    University of North Carolina, School of Medicine, Obstetrics and Gynecology, Chapel Hill, North Carolina, USA

  2. 2

    FHI 360, Clinical Sciences, Research Triangle Park, North Carolina, USA

  3. 3

    London Community Healthcare, Westside Contraceptive Services, London, UK

  4. 4

    Gynuity Health projects, New York, New York, USA

*David A Grimes, Obstetrics and Gynecology, University of North Carolina, School of Medicine, CB#7570, Chapel Hill, North Carolina, 27599-7570, USA. david_grimes@med.unc.edu.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 13 NOV 2013

SEARCH

[Analysis 1.1]
Analysis 1.1. Comparison 1 Desogestrel 75 μg versus levonorgestrel 30 μg daily, Outcome 1 Pregnancy.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Desogestrel 75 μg versus levonorgestrel 30 μg daily, Outcome 2 Discontinuation because of adverse events.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Desogestrel 75 μg versus levonorgestrel 30 μg daily, Outcome 3 Discontinuation because of irregular bleeding.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Desogestrel 75 μg versus levonorgestrel 30 μg daily, Outcome 4 Discontinuation for all reasons.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Mifepristone 5 mg versus levonorgestrel 30 μg daily, Outcome 1 Pregnancy.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Mifepristone 5 mg versus levonorgestrel 30 μg daily, Outcome 2 Amenorrhea.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Mifepristone 5 mg versus levonorgestrel 30 μg daily, Outcome 3 Mean endometrial thickness at 24 weeks.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Mifepristone 5 mg versus levonorgestrel 30 μg daily, Outcome 4 Endometrial biopsy to evaluate endometrial cavity >12 mm on ultrasound.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Ethynodiol diacetate 0.25 mg versus ethynodiol diacetate 1.0 mg plus mestranol 0.1 mg, Outcome 1 Irregular cycles.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Ethynodiol diacetate 0.25 mg versus ethynodiol diacetate 1.0 mg plus mestranol 0.1 mg, Outcome 2 Intercycle bleeding.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Ethynodiol diacetate 0.25 mg versus ethynodiol diacetate 1.0 mg plus mestranol 0.1 mg, Outcome 3 Discontinuation from trial.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Norethisterone acetate 0.3 mg versus norgestrel 0.075 mg, Outcome 1 Pregnancy.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Norethisterone acetate 0.3 mg versus norgestrel 0.075 mg, Outcome 2 Continuation at one year.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Norethisterone acetate 0.3 mg versus norgestrel 0.075 mg, Outcome 3 Discontinuation because of menstrual disturbance.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Norethisterone acetate 0.3 mg versus norgestrel 0.075 mg, Outcome 4 Discontinuation because of other side effects.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Norethisterone acetate 0.3 mg versus norgestrel 0.075 mg, Outcome 5 Discontinuation for reasons unconnected with treatment.